Taiwan consensus statement on the management of chronic hepatitis B

Publication date: Available online 6 December 2018Source: Journal of the Formosan Medical AssociationAuthor(s): Rong-Nan Chien, Jia-Horng Kao, Cheng-Yuan Peng, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Tsung-Hui Hu, Hwa-I Yang, Sheng-Nan Lu, Yen-Hsuan Ni, Won-Long Chuang, Chuan-Mo Lee, Jaw-Chin Wu, Pei-Jer Chen, Yun-Fan LiawThe experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the statement on HBV management before. However, there are more and more new data on the natural history and treatment of HBV infection in the past decade. These include new application of an old biomarker (quantitative HBsAg), clinical significance of HBV genotype and naturally occurring mutations, the role of non-invasive examination in evaluating severity of hepatic fibrosis, clinical significance of outcome calculators, new drug or new combination strategies towards more effective therapy and organ transplantation including liver and non-liver transplantation. It is time to publish the guidelines on HBV management of Taiwan. Hence, TASL have conducted an expert meeting to review, to discuss and to debate the relevant literatures, followed by draft the manuscript of HBV management guidelines and recommendations. The guidelines include general management, indicat...
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research